Bill Ackman Won Both Ways on Allergan Deal: George

The transcript discusses the major deal between Valiant and Allergan, highlighting the appeal of Allergan to both Valiant and Activists. It explores Bill Ackman's role and profit from the deal, the importance of R&D in the pharmaceutical industry, and the market dynamics involved. The discussion includes comparisons between Valiant, Activists, and other companies, and concludes with insights into future trends and challenges in the pharmaceutical sector.

What role does R&D play in the pharmaceutical industry according to the discussion?

How did the participants view the impact of activist investors on the pharmaceutical industry?

What was the perspective on the future of M&A in the pharmaceutical sector?